BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...Annexon Biosciences Inc. ANX005 Undisclosed Preclin Complement receptor 5A (C5AR1; C5AR; CD88) Alsonex Pty. Ltd. ALS-205...
...companies are targeting downstream complement proteins: Alsonex Pty. Ltd. and Complement Pharma. Alsonex’s lead candidate ALS-205...
...Managing Director Alan Robertson. The company will start a Phase I trial this quarter testing ALS-205...
BioCentury | Jul 11, 2017
Emerging Company Profile

Complementary ALS play

...thinks getting to a functional cure will require combining multiple mechanisms. The hypothesis is that ALS-205...
...professor of pharmacology. In March, Woodruff and colleagues reported in British Journal of Pharmacology that ALS-205...
...but Robertson said Alsonex attracted investors by getting FDA and EMA Orphan Drug designation for ALS-205...
Items per page:
1 - 2 of 2